Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906570103> ?p ?o ?g. }
- W2906570103 endingPage "1849.e16" @default.
- W2906570103 startingPage "1840" @default.
- W2906570103 abstract "Background & AimsHepatitis C virus (HCV)-related cirrhosis increases the risk for hepatocellular carcinoma (HCC). After a sustained virologic response (SVR) to anti-HCV therapy, the risk of HCC is reduced but not eliminated. Recent developments in antiviral therapy have increased rates of SVR markedly. Guidelines recommend indefinite biannual ultrasound surveillance after SVR for patients with advanced fibrosis before treatment. Surveillance for HCC is cost effective before anti-HCV treatment; we investigated whether it remains so after SVR.MethodsWe developed a Markov model to evaluate the cost effectiveness of biannual or annual HCC ultrasound surveillance vs no surveillance in 50-year-old patients with advanced fibrosis after an SVR to anti-HCV therapy. Parameter values were obtained from publications and expert opinions. Primary outcomes were quality-adjusted life-years (QALYs), costs, and the incremental cost-effectiveness ratios (ICERs).ResultsWith a constant 0.5% annual incidence of HCC, biannual and annual surveillance resulted in ICERs of $106,792 and $72,105 per QALY, respectively, with high false-positive rates. When surveillance was limited to patients with cirrhosis, but not F3 fibrosis, biannual surveillance likely was cost effective, with ICERs of $48,729 and $43,229 per QALY after treatment with interferon and direct-acting antiviral agents, respectively. In patients with F3 fibrosis, the incidence of HCC was 0.3% to 0.4% per year, leading to an ICER of $188,157 per QALY for biannual surveillance. If HCC incidence increases with age, surveillance becomes more cost effective but remains below willingness-to-pay thresholds only for patients with cirrhosis or with pretreatment aspartate aminotransferase to platelet ratio index greater than 2.0 or FIB-4 measurements greater than 3.25. Sensitivity analyses identified HCC incidence and transition rate to symptomatic disease without surveillance as factors that affect cost effectiveness.ConclusionsIn a Markov model, we found HCC surveillance after an SVR to HCV treatment to be cost effective for patients with cirrhosis, but not for patients with F3 fibrosis. Hepatitis C virus (HCV)-related cirrhosis increases the risk for hepatocellular carcinoma (HCC). After a sustained virologic response (SVR) to anti-HCV therapy, the risk of HCC is reduced but not eliminated. Recent developments in antiviral therapy have increased rates of SVR markedly. Guidelines recommend indefinite biannual ultrasound surveillance after SVR for patients with advanced fibrosis before treatment. Surveillance for HCC is cost effective before anti-HCV treatment; we investigated whether it remains so after SVR. We developed a Markov model to evaluate the cost effectiveness of biannual or annual HCC ultrasound surveillance vs no surveillance in 50-year-old patients with advanced fibrosis after an SVR to anti-HCV therapy. Parameter values were obtained from publications and expert opinions. Primary outcomes were quality-adjusted life-years (QALYs), costs, and the incremental cost-effectiveness ratios (ICERs). With a constant 0.5% annual incidence of HCC, biannual and annual surveillance resulted in ICERs of $106,792 and $72,105 per QALY, respectively, with high false-positive rates. When surveillance was limited to patients with cirrhosis, but not F3 fibrosis, biannual surveillance likely was cost effective, with ICERs of $48,729 and $43,229 per QALY after treatment with interferon and direct-acting antiviral agents, respectively. In patients with F3 fibrosis, the incidence of HCC was 0.3% to 0.4% per year, leading to an ICER of $188,157 per QALY for biannual surveillance. If HCC incidence increases with age, surveillance becomes more cost effective but remains below willingness-to-pay thresholds only for patients with cirrhosis or with pretreatment aspartate aminotransferase to platelet ratio index greater than 2.0 or FIB-4 measurements greater than 3.25. Sensitivity analyses identified HCC incidence and transition rate to symptomatic disease without surveillance as factors that affect cost effectiveness. In a Markov model, we found HCC surveillance after an SVR to HCV treatment to be cost effective for patients with cirrhosis, but not for patients with F3 fibrosis." @default.
- W2906570103 created "2019-01-01" @default.
- W2906570103 creator A5008282524 @default.
- W2906570103 creator A5009025959 @default.
- W2906570103 creator A5014738777 @default.
- W2906570103 creator A5023511246 @default.
- W2906570103 creator A5029652421 @default.
- W2906570103 creator A5032844648 @default.
- W2906570103 creator A5045283839 @default.
- W2906570103 creator A5049864482 @default.
- W2906570103 creator A5064563250 @default.
- W2906570103 creator A5075877490 @default.
- W2906570103 creator A5085712795 @default.
- W2906570103 date "2019-08-01" @default.
- W2906570103 modified "2023-10-17" @default.
- W2906570103 title "Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis" @default.
- W2906570103 cites W112319137 @default.
- W2906570103 cites W1968751272 @default.
- W2906570103 cites W1971837077 @default.
- W2906570103 cites W1973935979 @default.
- W2906570103 cites W1980154502 @default.
- W2906570103 cites W1984588394 @default.
- W2906570103 cites W1994106833 @default.
- W2906570103 cites W1996109529 @default.
- W2906570103 cites W2003307697 @default.
- W2906570103 cites W2006184344 @default.
- W2906570103 cites W2006916640 @default.
- W2906570103 cites W2015381959 @default.
- W2906570103 cites W2016071077 @default.
- W2906570103 cites W2025487438 @default.
- W2906570103 cites W2027128854 @default.
- W2906570103 cites W2038280383 @default.
- W2906570103 cites W2039677460 @default.
- W2906570103 cites W2048457974 @default.
- W2906570103 cites W2048727592 @default.
- W2906570103 cites W2049476914 @default.
- W2906570103 cites W2054243454 @default.
- W2906570103 cites W2060897792 @default.
- W2906570103 cites W2065190187 @default.
- W2906570103 cites W2067182451 @default.
- W2906570103 cites W2068779367 @default.
- W2906570103 cites W207017637 @default.
- W2906570103 cites W2076007540 @default.
- W2906570103 cites W2092634991 @default.
- W2906570103 cites W2098637324 @default.
- W2906570103 cites W2105027040 @default.
- W2906570103 cites W2127313936 @default.
- W2906570103 cites W2132451316 @default.
- W2906570103 cites W2143618093 @default.
- W2906570103 cites W2150023812 @default.
- W2906570103 cites W2150300426 @default.
- W2906570103 cites W2150433939 @default.
- W2906570103 cites W2155310622 @default.
- W2906570103 cites W2163403599 @default.
- W2906570103 cites W2168076454 @default.
- W2906570103 cites W2171104739 @default.
- W2906570103 cites W2291726879 @default.
- W2906570103 cites W2333367339 @default.
- W2906570103 cites W2335913920 @default.
- W2906570103 cites W2536609598 @default.
- W2906570103 cites W2544387958 @default.
- W2906570103 cites W2556028914 @default.
- W2906570103 cites W2582878252 @default.
- W2906570103 cites W2605644052 @default.
- W2906570103 cites W2625029889 @default.
- W2906570103 cites W2755717717 @default.
- W2906570103 cites W4243625103 @default.
- W2906570103 cites W4245784696 @default.
- W2906570103 doi "https://doi.org/10.1016/j.cgh.2018.12.018" @default.
- W2906570103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30580095" @default.
- W2906570103 hasPublicationYear "2019" @default.
- W2906570103 type Work @default.
- W2906570103 sameAs 2906570103 @default.
- W2906570103 citedByCount "72" @default.
- W2906570103 countsByYear W29065701032019 @default.
- W2906570103 countsByYear W29065701032020 @default.
- W2906570103 countsByYear W29065701032021 @default.
- W2906570103 countsByYear W29065701032022 @default.
- W2906570103 countsByYear W29065701032023 @default.
- W2906570103 crossrefType "journal-article" @default.
- W2906570103 hasAuthorship W2906570103A5008282524 @default.
- W2906570103 hasAuthorship W2906570103A5009025959 @default.
- W2906570103 hasAuthorship W2906570103A5014738777 @default.
- W2906570103 hasAuthorship W2906570103A5023511246 @default.
- W2906570103 hasAuthorship W2906570103A5029652421 @default.
- W2906570103 hasAuthorship W2906570103A5032844648 @default.
- W2906570103 hasAuthorship W2906570103A5045283839 @default.
- W2906570103 hasAuthorship W2906570103A5049864482 @default.
- W2906570103 hasAuthorship W2906570103A5064563250 @default.
- W2906570103 hasAuthorship W2906570103A5075877490 @default.
- W2906570103 hasAuthorship W2906570103A5085712795 @default.
- W2906570103 hasBestOaLocation W29065701031 @default.
- W2906570103 hasConcept C112930515 @default.
- W2906570103 hasConcept C120665830 @default.
- W2906570103 hasConcept C121332964 @default.
- W2906570103 hasConcept C126322002 @default.
- W2906570103 hasConcept C143998085 @default.
- W2906570103 hasConcept C203014093 @default.